- Home
- UNCY vs CBUS Comparison
UNCY vs CBUS Comparison
Compare UNCY & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | CBUS |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 121.1M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | UNCY | CBUS |
|---|---|---|
| Price | $7.32 | $1.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $25.67 | $9.00 |
| AVG Volume (30 Days) | ★ 765.0K | 268.4K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.33 |
| EPS | N/A | ★ N/A |
| Revenue | $675,000.00 | ★ $3,639,000.00 |
| Revenue This Year | N/A | $112.72 |
| Revenue Next Year | $582.86 | $83.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.72 | $1.09 |
| 52 Week High | $8.74 | $4.19 |
Technical Indicators
Market Signals| Indicator | UNCY | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 38.97 |
| Support Level | $6.81 | $1.24 |
| Resistance Level | $7.43 | $1.51 |
| Average True Range (ATR) | 0.58 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 41.43 | 21.82 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.